 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase or decrease the risk [0m
[34mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase or decrease the risk [0m
[32mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ALENDRONATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ALENDRONATE: pharmacodynamics: [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the [0m
[31mbone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled [0m
[31mduring bone turnover. Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of [0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. ALENDRONATE: pharmacodynamics: These changes result[0m
[31min progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m,[0m
[31mthe risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or more [0m
[31mosteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. [0m
[31mALENDRONATE: pharmacodynamics: Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of [0m
[31mbone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. These [0m
[31mbiochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. Long-term [0m
[31mtreatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l [0m
[31mcollagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. ALENDRONATE: pharmacodynamics: Similar decreases were seen in patients in [0m
[31mosteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months [0m
[31mreached a plateau that was maintained for the entire duration of treatment with alendronate sodium. In osteoporosis treatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone [0m
[31mformation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In [0m
[31mosteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by approximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: pregnancy: The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration [0m
[1;31m([0m[31mintravenous versus oral[0m[1;31m)[0m[31m on the risk has not been studied. The estimated background risk of major birth defects and miscarriage for the indicated [0m[1;31mpopulation[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m is unknown. All pregnancies have a [0m
[31mbackground risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized [0m
[31mpregnancies is [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m-[0m[1;31m20[0m[31m%, respectively. Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased postimplantation [0m
[31msurvival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, mg/m [0m[1;31m2[0m[31m . [0m
[31mALENDRONATE: pregnancy: Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to approximately [0m
[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m [0m
[31mresulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at [0m[1;31m0.5[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. ALENDRONATE: pregnancy: Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m [0m
[31mtimes the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking [0m
[31mwater or by subcutaneous minipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. However, [0m
[31mintravenous calcium supplementation prevented maternal, but not neonatal deaths.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: use_in_specific_populations: Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased postimplantation [0m
[31msurvival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, mg/m [0m[1;31m2[0m[31m . Incidence[0m
[31mof incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical [0m
[31mdaily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to approximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. [0m
[31mALENDRONATE: use_in_specific_populations: Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m [0m
[31mresulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at [0m[1;31m0.5[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical[0m
[31mdaily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking water or by subcutaneous [0m
[31mminipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. ALENDRONATE: [0m
[31muse_in_specific_populations: However, intravenous calcium supplementation prevented maternal, but not neonatal deaths. [0m[1;31m8.2[0m[31m Lactation Risk Summary It is not known whether alendronate is present in [0m
[31mhuman breast milk, affects human milk production, or has effects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical [0m
[31mneed for BINOSTO and any potential adverse effects on the breastfed child from BINOSTO or from the underlying maternal condition. [0m[1;31m8.4[0m[31m Pediatric Use BINOSTO is not indicated for use in pediatric [0m
[31mpatients. The safety and efficacy of alendronate sodium were examined in a randomized, double-blind, placebo-controlled two-year study of [0m[1;31m139[0m[31m pediatric patients, aged [0m[1;31m4[0m[31m-[0m[1;31m18[0m[31m years, with severe [0m
[31mosteogenesis imperfecta [0m[1;31m([0m[31mOI[0m[1;31m)[0m[31m. ALENDRONATE: use_in_specific_populations: One-hundred-and-nine patients were randomized to [0m[1;31m5[0m[31m mg alendronate sodium daily [0m[1;31m([0m[31mweight less than [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m or [0m[1;31m10[0m[31m mg alendronate [0m
[31msodium daily [0m[1;31m([0m[31mweight greater than or equal to [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m and [0m[1;31m30[0m[31m patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was [0m[1;31m-4.5[0m[31m. The mean change in lumbar spine BMD Z-score from [0m
[31mbaseline to Month [0m[1;31m24[0m[31m was [0m[1;31m1.3[0m[31m in the alendronate-treated patients and [0m[1;31m0.1[0m[31m in the placebo- treated patients. Treatment with alendronate sodium did not reduce the risk of fracture. Sixteen percent of the[0m
[31malendronate-treated patients who sustained a radiologically-confirmed fracture by Month [0m[1;31m12[0m[31m of the study had delayed fracture healing [0m[1;31m([0m[31mcallus remodeling[0m[1;31m)[0m[31m or fracture non-union when assessed [0m
[31mradiographically at Month [0m[1;31m24[0m[31m compared with [0m[1;31m9[0m[31m% of the placebo-treated patients. ALENDRONATE: use_in_specific_populations: In alendronate-treated patients, bone histomorphometry data obtained at Month [0m
[1;31m24[0m[31m demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between the alendronate [0m
[31msodium and placebo groups in reduction of bone pain. The oral bioavailability in children was similar to that observed in adults. The overall safety profile of alendronate sodium in osteogenesis [0m
[31mimperfecta patients treated for up to [0m[1;31m24[0m[31m months was generally similar to that of adults with osteoporosis treated with alendronate sodium. However, there was an increased occurrence of vomiting in [0m
[31mosteogenesis imperfecta patients treated with alendronate sodium compared to placebo. During the [0m[1;31m24[0m[31m-month treatment period, vomiting was observed in [0m[1;31m32[0m[31m of [0m[1;31m109[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m patients treated with alendronate[0m
[31msodium and [0m[1;31m3[0m[31m of [0m[1;31m30[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m patients treated with placebo.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE increase or decrease the risk of [0m
[31mmortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase or decrease the risk [0m
[32mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE: pharmacodynamics: [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the [0m
[31mbone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled [0m
[31mduring bone turnover. Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of [0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. ALENDRONATE: pharmacodynamics: These changes result[0m
[31min progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m,[0m
[31mthe risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or more [0m
[31mosteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. [0m
[31mALENDRONATE: pharmacodynamics: Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of [0m
[31mbone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. These [0m
[31mbiochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. Long-term [0m
[31mtreatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l [0m
[31mcollagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. ALENDRONATE: pharmacodynamics: Similar decreases were seen in patients in [0m
[31mosteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months [0m
[31mreached a plateau that was maintained for the entire duration of treatment with alendronate sodium. In osteoporosis treatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone [0m
[31mformation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In [0m
[31mosteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by approximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: pregnancy: The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration [0m
[1;31m([0m[31mintravenous versus oral[0m[1;31m)[0m[31m on the risk has not been studied. The estimated background risk of major birth defects and miscarriage for the indicated [0m[1;31mpopulation[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m is unknown. All pregnancies have a [0m
[31mbackground risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized [0m
[31mpregnancies is [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m-[0m[1;31m20[0m[31m%, respectively. Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased postimplantation [0m
[31msurvival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, mg/m [0m[1;31m2[0m[31m . [0m
[31mALENDRONATE: pregnancy: Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to approximately [0m
[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m [0m
[31mresulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at [0m[1;31m0.5[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. ALENDRONATE: pregnancy: Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m [0m
[31mtimes the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking [0m
[31mwater or by subcutaneous minipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. However, [0m
[31mintravenous calcium supplementation prevented maternal, but not neonatal deaths.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: use_in_specific_populations: Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased postimplantation [0m
[31msurvival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, mg/m [0m[1;31m2[0m[31m . Incidence[0m
[31mof incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical [0m
[31mdaily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to approximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. [0m
[31mALENDRONATE: use_in_specific_populations: Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m [0m
[31mresulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at [0m[1;31m0.5[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical[0m
[31mdaily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking water or by subcutaneous [0m
[31mminipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. ALENDRONATE: [0m
[31muse_in_specific_populations: However, intravenous calcium supplementation prevented maternal, but not neonatal deaths. [0m[1;31m8.2[0m[31m Lactation Risk Summary It is not known whether alendronate is present in [0m
[31mhuman breast milk, affects human milk production, or has effects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical [0m
[31mneed for BINOSTO and any potential adverse effects on the breastfed child from BINOSTO or from the underlying maternal condition. [0m[1;31m8.4[0m[31m Pediatric Use BINOSTO is not indicated for use in pediatric [0m
[31mpatients. The safety and efficacy of alendronate sodium were examined in a randomized, double-blind, placebo-controlled two-year study of [0m[1;31m139[0m[31m pediatric patients, aged [0m[1;31m4[0m[31m-[0m[1;31m18[0m[31m years, with severe [0m
[31mosteogenesis imperfecta [0m[1;31m([0m[31mOI[0m[1;31m)[0m[31m. ALENDRONATE: use_in_specific_populations: One-hundred-and-nine patients were randomized to [0m[1;31m5[0m[31m mg alendronate sodium daily [0m[1;31m([0m[31mweight less than [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m or [0m[1;31m10[0m[31m mg alendronate [0m
[31msodium daily [0m[1;31m([0m[31mweight greater than or equal to [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m and [0m[1;31m30[0m[31m patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was [0m[1;31m-4.5[0m[31m. The mean change in lumbar spine BMD Z-score from [0m
[31mbaseline to Month [0m[1;31m24[0m[31m was [0m[1;31m1.3[0m[31m in the alendronate-treated patients and [0m[1;31m0.1[0m[31m in the placebo- treated patients. Treatment with alendronate sodium did not reduce the risk of fracture. Sixteen percent of the[0m
[31malendronate-treated patients who sustained a radiologically-confirmed fracture by Month [0m[1;31m12[0m[31m of the study had delayed fracture healing [0m[1;31m([0m[31mcallus remodeling[0m[1;31m)[0m[31m or fracture non-union when assessed [0m
[31mradiographically at Month [0m[1;31m24[0m[31m compared with [0m[1;31m9[0m[31m% of the placebo-treated patients. ALENDRONATE: use_in_specific_populations: In alendronate-treated patients, bone histomorphometry data obtained at Month [0m
[1;31m24[0m[31m demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between the alendronate [0m
[31msodium and placebo groups in reduction of bone pain. The oral bioavailability in children was similar to that observed in adults. The overall safety profile of alendronate sodium in osteogenesis [0m
[31mimperfecta patients treated for up to [0m[1;31m24[0m[31m months was generally similar to that of adults with osteoporosis treated with alendronate sodium. However, there was an increased occurrence of vomiting in [0m
[31mosteogenesis imperfecta patients treated with alendronate sodium compared to placebo. During the [0m[1;31m24[0m[31m-month treatment period, vomiting was observed in [0m[1;31m32[0m[31m of [0m[1;31m109[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m patients treated with alendronate[0m
[31msodium and [0m[1;31m3[0m[31m of [0m[1;31m30[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m patients treated with placebo.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase or decrease the risk [0m
[32mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE increase or decrease the risk of [0m
[31mmortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase or decrease the risk [0m
[32mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ALENDRONATE: pharmacodynamics: [0m[1;31m12.2[0m[31m Pharmacodynamics Alendronate is a bisphosphonate that binds to bone hydroxyapatite and specifically inhibits the activity of osteoclasts, the [0m
[31mbone-resorbing cells. Alendronate reduces bone resorption with no direct effect on bone formation, although the latter process is ultimately reduced because bone resorption and formation are coupled [0m
[31mduring bone turnover. Osteoporosis in Postmenopausal Women Osteoporosis is characterized by low bone mass that leads to an increased risk of fracture. The diagnosis can be confirmed by the finding of [0m
[31mlow bone mass, evidence of fracture on x-ray, a history of osteoporotic fracture, or height loss or kyphosis, indicative of vertebral [0m[1;31m([0m[31mspinal[0m[1;31m)[0m[31m fracture. Osteoporosis occurs in both males and females [0m
[31mbut is most common among women following the menopause, when bone turnover increases and the rate of bone resorption exceeds that of bone formation. ALENDRONATE: pharmacodynamics: These changes result[0m
[31min progressive bone loss and lead to osteoporosis in a significant proportion of women over age [0m[1;31m50[0m[31m. Fractures, usually of the spine, hip, and wrist, are the common consequences. From age [0m[1;31m50[0m[31m to age [0m[1;31m90[0m[31m,[0m
[31mthe risk of hip fracture in white women increases [0m[1;31m50[0m[31m-fold and the risk of vertebral fracture [0m[1;31m15[0m[31m- to [0m[1;31m30[0m[31m-fold. It is estimated that approximately [0m[1;31m40[0m[31m% of [0m[1;31m50[0m[31m-year-old women will sustain one or more [0m
[31mosteoporosis-related fractures of the spine, hip, or wrist during their remaining lifetimes. Hip fractures, in particular, are associated with substantial morbidity, disability, and mortality. [0m
[31mALENDRONATE: pharmacodynamics: Daily oral doses of alendronate sodium [0m[1;31m([0m[1;31m5[0m[31m, [0m[1;31m20[0m[31m, and [0m[1;31m40[0m[31m mg for six weeks[0m[1;31m)[0m[31m in postmenopausal women produced biochemical changes indicative of dose-dependent inhibition of [0m
[31mbone resorption, including decreases in urinary calcium and urinary markers of bone collagen degradation [0m[1;31m([0m[31msuch as deoxypyridinoline and cross-linked N-telopeptides of type I collagen[0m[1;31m)[0m[31m. These [0m
[31mbiochemical changes tended to return toward baseline values as early as [0m[1;31m3[0m[31m weeks following the discontinuation of therapy with alendronate and did not differ from placebo after [0m[1;31m7[0m[31m months. Long-term [0m
[31mtreatment of osteoporosis with alendronate sodium [0m[1;31m10[0m[31m mg/day [0m[1;31m([0m[31mfor up to five years[0m[1;31m)[0m[31m reduced urinary excretion of markers of bone resorption, deoxypyridinoline and cross-linked N-telopeptides of type l [0m
[31mcollagen, by approximately [0m[1;31m50[0m[31m% and [0m[1;31m70[0m[31m%, respectively, to reach levels similar to those seen in healthy premenopausal women. ALENDRONATE: pharmacodynamics: Similar decreases were seen in patients in [0m
[31mosteoporosis prevention studies who received alendronate sodium [0m[1;31m5[0m[31m mg/day. The decrease in the rate of bone resorption indicated by these markers was evident as early as [0m[1;31m1[0m[31m month and at [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m months [0m
[31mreached a plateau that was maintained for the entire duration of treatment with alendronate sodium. In osteoporosis treatment studies alendronate sodium [0m[1;31m10[0m[31m mg/day decreased the markers of bone [0m
[31mformation, osteocalcin and bone specific alkaline phosphatase by approximately [0m[1;31m50[0m[31m%, and total serum alkaline phosphatase by approximately [0m[1;31m25[0m[31m to [0m[1;31m30[0m[31m% to reach a plateau after [0m[1;31m6[0m[31m to [0m[1;31m12[0m[31m months. In [0m
[31mosteoporosis prevention studies alendronate sodium [0m[1;31m5[0m[31m mg/day decreased osteocalcin and total serum alkaline phosphatase by approximately [0m[1;31m40[0m[31m% and [0m[1;31m15[0m[31m%, respectively.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: pregnancy: The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration [0m
[1;31m([0m[31mintravenous versus oral[0m[1;31m)[0m[31m on the risk has not been studied. The estimated background risk of major birth defects and miscarriage for the indicated [0m[1;31mpopulation[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m is unknown. All pregnancies have a [0m
[31mbackground risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized [0m
[31mpregnancies is [0m[1;31m2[0m[31m-[0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m-[0m[1;31m20[0m[31m%, respectively. Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased postimplantation [0m
[31msurvival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, mg/m [0m[1;31m2[0m[31m . [0m
[31mALENDRONATE: pregnancy: Incidence of incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to approximately [0m
[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m [0m
[31mresulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at [0m[1;31m0.5[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. ALENDRONATE: pregnancy: Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m [0m
[31mtimes the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking [0m
[31mwater or by subcutaneous minipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. However, [0m
[31mintravenous calcium supplementation prevented maternal, but not neonatal deaths.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m


[31mCONTENT: ALENDRONATE: use_in_specific_populations: Data Animal Data Reproduction studies in rats dosed orally from before mating to the end of gestation or lactation showed decreased postimplantation [0m
[31msurvival starting at [0m[1;31m2[0m[31m mg/kg/day and decreased body weight gain starting at [0m[1;31m1[0m[31m mg/kg/day, doses equivalent to less than half the [0m[1;31m40[0m[31m mg clinical daily dose based on body surface area, mg/m [0m[1;31m2[0m[31m . Incidence[0m
[31mof incomplete fetal ossification in vertebral, skull, and sternebral bones were increased in rats dosed orally during organogenesis starting at [0m[1;31m10[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m3[0m[31m times the [0m[1;31m40[0m[31m mg clinical [0m
[31mdaily dose[0m[1;31m)[0m[31m. No similar fetal effects were observed in pregnant rabbits dosed orally during organogenesis at up to [0m[1;31m35[0m[31m mg/kg/day [0m[1;31m([0m[31mequivalent to approximately [0m[1;31m10[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. [0m
[31mALENDRONATE: use_in_specific_populations: Both total and ionized calcium decreased in pregnant rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m [0m
[31mresulting in delays and failures of delivery. Protracted parturition due to maternal hypocalcemia was observed when rats were treated from before mating through gestation starting at [0m[1;31m0.5[0m[31m mg/kg/day [0m
[1;31m([0m[31mapproximately one tenth the [0m[1;31m40[0m[31m mg clinical daily dose[0m[1;31m)[0m[31m. Maternotoxicity [0m[1;31m([0m[31mlate pregnancy deaths[0m[1;31m)[0m[31m also occurred in female rats treated orally with [0m[1;31m15[0m[31m mg/kg/day [0m[1;31m([0m[31mapproximately [0m[1;31m4[0m[31m times the [0m[1;31m40[0m[31m mg clinical[0m
[31mdaily dose[0m[1;31m)[0m[31m for varying gestational time periods. These maternal deaths were lessened but not eliminated by cessation of treatment. Calcium supplementation in the drinking water or by subcutaneous [0m
[31mminipump to rats dosed orally with [0m[1;31m15[0m[31m mg/kg/day alendronate could not ameliorate the hypocalcemia or prevent the dystocia-related maternal and neonatal deaths. ALENDRONATE: [0m
[31muse_in_specific_populations: However, intravenous calcium supplementation prevented maternal, but not neonatal deaths. [0m[1;31m8.2[0m[31m Lactation Risk Summary It is not known whether alendronate is present in [0m
[31mhuman breast milk, affects human milk production, or has effects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical [0m
[31mneed for BINOSTO and any potential adverse effects on the breastfed child from BINOSTO or from the underlying maternal condition. [0m[1;31m8.4[0m[31m Pediatric Use BINOSTO is not indicated for use in pediatric [0m
[31mpatients. The safety and efficacy of alendronate sodium were examined in a randomized, double-blind, placebo-controlled two-year study of [0m[1;31m139[0m[31m pediatric patients, aged [0m[1;31m4[0m[31m-[0m[1;31m18[0m[31m years, with severe [0m
[31mosteogenesis imperfecta [0m[1;31m([0m[31mOI[0m[1;31m)[0m[31m. ALENDRONATE: use_in_specific_populations: One-hundred-and-nine patients were randomized to [0m[1;31m5[0m[31m mg alendronate sodium daily [0m[1;31m([0m[31mweight less than [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m or [0m[1;31m10[0m[31m mg alendronate [0m
[31msodium daily [0m[1;31m([0m[31mweight greater than or equal to [0m[1;31m40[0m[31m kg[0m[1;31m)[0m[31m and [0m[1;31m30[0m[31m patients to placebo. The mean baseline lumbar spine BMD Z-score of the patients was [0m[1;31m-4.5[0m[31m. The mean change in lumbar spine BMD Z-score from [0m
[31mbaseline to Month [0m[1;31m24[0m[31m was [0m[1;31m1.3[0m[31m in the alendronate-treated patients and [0m[1;31m0.1[0m[31m in the placebo- treated patients. Treatment with alendronate sodium did not reduce the risk of fracture. Sixteen percent of the[0m
[31malendronate-treated patients who sustained a radiologically-confirmed fracture by Month [0m[1;31m12[0m[31m of the study had delayed fracture healing [0m[1;31m([0m[31mcallus remodeling[0m[1;31m)[0m[31m or fracture non-union when assessed [0m
[31mradiographically at Month [0m[1;31m24[0m[31m compared with [0m[1;31m9[0m[31m% of the placebo-treated patients. ALENDRONATE: use_in_specific_populations: In alendronate-treated patients, bone histomorphometry data obtained at Month [0m
[1;31m24[0m[31m demonstrated decreased bone turnover and delayed mineralization time; however, there were no mineralization defects. There were no statistically significant differences between the alendronate [0m
[31msodium and placebo groups in reduction of bone pain. The oral bioavailability in children was similar to that observed in adults. The overall safety profile of alendronate sodium in osteogenesis [0m
[31mimperfecta patients treated for up to [0m[1;31m24[0m[31m months was generally similar to that of adults with osteoporosis treated with alendronate sodium. However, there was an increased occurrence of vomiting in [0m
[31mosteogenesis imperfecta patients treated with alendronate sodium compared to placebo. During the [0m[1;31m24[0m[31m-month treatment period, vomiting was observed in [0m[1;31m32[0m[31m of [0m[1;31m109[0m[31m [0m[1;31m([0m[1;31m29.4[0m[31m%[0m[1;31m)[0m[31m patients treated with alendronate[0m
[31msodium and [0m[1;31m3[0m[31m of [0m[1;31m30[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m patients treated with placebo.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE increase or decrease the risk [0m
[32mof mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ALENDRONATE increase or decrease the risk of [0m
[31mmortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-ALENDRONATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label data does not specify whether alendronate increases or decreases the risk of mortality after myocardial infarction. Therefore, we cannot determine the effect of alendronate on mortality [0m
[32mpost-myocardial infarction based on the available FDA label information.[0m
